Reteplase

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Reteplase
Clinical data
Trade names Retavase
AHFS/Drugs.com monograph
Legal status ?
Identifiers
CAS number 133652-38-7 YesY
ATC code B01AD07
DrugBank DB00015
UNII DQA630RIE9 YesY
KEGG D05721 YesY
Chemical data
Formula C1736H2671N499O522S22 
Mol. mass 39589.6 g/mol
 YesY (what is this?)  (verify)

Reteplase (trade names Retavase, Rapilysin) is a thrombolytic drug, used to treat heart attacks by breaking up the clots that cause them.

Reteplase is a recombinant non-glycosylated form of human tissue plasminogen activator, which has been modified to contain 357 of the 527 amino acids of the original protein. It is produced in the bacterium Escherichia coli.[citation needed]

Reteplase is similar to recombinant human tissue plasminogen activator (alteplase), but the modifications give reteplase a longer half-life of 13–16 minutes. Reteplase also binds fibrin with lower affinity than alteplase, improving its ability to penetrate into clots.

Reteplase was approved by the Food and Drug Administration in 1996.

As reteplase is able to penetrate inside the thrombi, an enhanced fibrinolytic activity will be achieved → rapid reperfusion → low incidence of bleeding.